A5007426598- Clostridium difficile and Clostridium perfringens research
- Nosocomial Infections in ICU
- Bacterial Identification and Susceptibility Testing
- Antimicrobial Resistance in Staphylococcus
- Gut microbiota and health
- SARS-CoV-2 and COVID-19 Research
- Pneumonia and Respiratory Infections
- COVID-19 Clinical Research Studies
- Antibiotic Use and Resistance
- Antibiotic Resistance in Bacteria
- Microscopic Colitis
- Streptococcal Infections and Treatments
- Antibiotics Pharmacokinetics and Efficacy
- Infective Endocarditis Diagnosis and Management
- Long-Term Effects of COVID-19
- Sepsis Diagnosis and Treatment
- SARS-CoV-2 detection and testing
- Viral gastroenteritis research and epidemiology
- COVID-19 and Mental Health
- Herpesvirus Infections and Treatments
- Respiratory viral infections research
- Medical Device Sterilization and Disinfection
- Urinary Tract Infections Management
- Blood disorders and treatments
- Infectious Encephalopathies and Encephalitis
Beaumont Hospital, Troy
2023-2025
Oakland University
2016-2025
Northwell Health
2025
Corewell Health
2023-2025
Beaumont Health
2014-2024
Michigan United
2024
Beaumont Hospital, Royal Oak
2010-2023
Royal Oak Community Coalition
2012-2021
Doctors Company (United States)
2018
University of Missouri
2017
Current therapies for recurrent Clostridioides difficile infection do not address the disrupted microbiome, which supports C. spore germination into toxin-producing bacteria. SER-109 is an investigational microbiome therapeutic composed of purified Firmicutes spores treatment infection.We conducted a phase 3, double-blind, randomized, placebo-controlled trial in patients who had three or more episodes (inclusive qualifying acute episode) received placebo (four capsules daily 3 days) after...
BackgroundPneumonia and bloodstream infections (BSI) due to extensively drug-resistant (XDR) Acinetobacter baumannii, XDR Pseudomonas aeruginosa, carbapenem-resistant Enterobacterales (CRE) are associated with high mortality rates, therapeutic options remain limited. This trial assessed whether combination therapy colistin meropenem was superior monotherapy for the treatment of these infections.MethodsThe OVERCOME (Colistin Monotherapy versus Combination Therapy) an international,...
Importance A safe and effective treatment for recurrent Clostridioides difficile infection (CDI) is urgently needed. Antibiotics kill toxin-producing bacteria but do not repair the disrupted microbiome, which promotes spore germination recurrence. Objectives To evaluate safety rate of CDI recurrence after administration investigational microbiome therapeutic SER-109 through 24 weeks. Design, Setting, Participants This phase 3, single-arm, open-label trial (ECOSPOR IV) was conducted at 72 US...
The β-lactamase inhibitor relebactam can restore imipenem activity against non-susceptible pathogens.To explore relebactam's safety, tolerability and efficacy, we conducted a randomized (1:1:1), controlled, Phase 2 trial comparing imipenem/cilastatin+relebactam 250 mg, 125 mg imipenem/cilastatin alone in adults with complicated urinary tract infections (cUTI) or acute pyelonephritis, regardless of baseline pathogen susceptibility. Treatment was administered intravenously every 6 h for 4-14...
Abstract Background Vancomycin is the most commonly administered antibiotic in hospitalized patients, but optimal exposure targets remain controversial. To clarify therapeutic range, this study evaluated association between vancomycin and outcomes patients with methicillin-resistant Staphylococcus aureus (MRSA) bacteremia. Methods This was a prospective, multicenter (n = 14), observational of 265 adults MRSA bacteremia treated vancomycin. The primary outcome treatment failure (TF), defined...
Remdesivir is efficacious for severe coronavirus disease 2019 (COVID-19) in adults, but data pregnant women are limited. We describe outcomes the first 86 with COVID-19 who were treated remdesivir.The reported span 21 March to 16 June 2020 hospitalized polymerase chain reaction-confirmed acute respiratory syndrome 2 infection and room air oxygen saturation ≤94% whose clinicians requested remdesivir through compassionate use program. The intended treatment course was 10 days (200 mg on day 1,...
<h3>Importance</h3> The appropriate duration of antibiotics for staphylococcal bacteremia is unknown. <h3>Objective</h3> To test whether an algorithm that defines treatment vs standard care provides noninferior efficacy without increasing severe adverse events. <h3>Design, Setting, and Participants</h3> A randomized trial involving adults with was conducted at 16 academic medical centers in the United States (n = 15) Spain 1) from April 2011 to March 2017. Patients were followed up 42 days...
BackgroundAlthough the risk of exposure to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is higher for frontline healthcare workers, not all personnel have similar risks. Determining infection rate difficult due limits on testing and high asymptomatic individuals. Detection antibodies against SARS-CoV-2 may be useful determining prior virus assessing mitigation strategies, such as isolation, masks, other protective equipment.
Bronchoalveolar lavage (BAL) culture is a standard, though time-consuming, approach for identifying microorganisms in patients with severe lower respiratory tract (LRT) infections. The sensitivity of BAL relatively low, and prior antimicrobial therapy decreases the further, leading to overuse empirical antibiotics. Unyvero LRT Application (Curetis GmbH, Germany) multiplex molecular panel that detects 19 bacteria, 10 antibiotic resistance markers, fungus, Pneumocystis jirovecii, fluid ∼4.5 h....
Although comorbidities are risk factors for recurrent Clostridioides difficile infection (rCDI), many clinical trials exclude patients with medical conditions such as malignancy or immunosuppression. In a phase 3, double-blind, placebo-controlled, randomized trial (ECOSPOR III), fecal microbiota spores, live (VOWST, Seres Therapeutics; hereafter "VOS," formerly SER-109), an oral therapeutic, significantly reduced the of rCDI at week 8. We evaluated efficacy VOS compared placebo in and other rCDI.
This study examines adverse events and durability of response SER-109, an investigational microbiome therapeutic comprised purified Firmicutes spores, compared with placebo for Clostridioides difficile infection.
Abstract Background Patients experiencing ≥1 recurrence of CDI are at elevated risk for subsequent recurrences and complications versus those with an initial episode. Treatment selection recurrent (rCDI) is influenced by the number a patient has experienced. Fecal microbiota spores, live-brpk (VOWST™; formerly SER-109, hereafter referred to as VOS Vowst Oral Spores) oral microbiota-based therapeutic prevent rCDI in adults after antibacterial treatment rCDI, thought work enabling rapid...
Abstract Background Clostridioides difficile infection (CDI) is one of the five urgent threats identified by Centers for Diseases Control and Prevention (CDC). In addition to actual infection, C. can colonize patients, particularly those with other gastrointestinal pathologies frequent healthcare exposure. Several studies have shown potential benefit secondary prophylaxis prevent recurrence CDI in patients a recent prior infection. The Screening Prophylax against study (StoP CDI) was double...
Defining physiology and methods to measure biological mechanisms is essential. Extensive datasets such as RNA sequencing are used with little analysis of the knowledge gained from various methodologies. Within this work, we have processed publicly available NCBI RNAseq using a combination bioinformatics tools for largest physiological organ, skin. In many datasets, identify quality sample, human transcript mapping, sex each foreign bacteria/viruses/protists, presence B/T-cell immune...
An abstract is not available for this content so a preview has been provided. Please use the Get access link above information on how to content.
A label free lectin biosensor developed in our laboratory that can quantitatively measure the binding between immobilized at carbohydrate sensor surface and lipopolysaccharide (LPS) on Gram-negative bacteria was demonstrated for an antibiotic susceptibility assay. The utilizes a polythiophene interface containing fused quinone moieties glycosylated to form platform immobilization of Concanavalin (Con A) is capable LPS measurements via orthogonal quartz crystal microbalance electrochemical...
OBJECTIVES: To identify and validate novel COVID-19 subphenotypes with potential heterogenous treatment effects (HTEs) using electronic health record (EHR) data 33 unique biomarkers. DESIGN: Retrospective cohort study of adults presenting for acute care, analysis biomarkers from residual blood collected during routine clinical care. Latent profile (LPA) biomarker EHR identified inpatients, which were validated a separate patients. HTE glucocorticoid use among was evaluated both an adjusted...
Intravenous (i.v.) minocycline is increasingly used to treat infections caused by multidrug-resistant (MDR) Acinetobacter baumannii . Despite its being approved nearly 50 years ago, published information on pharmacokinetic (PK) profile limited. This multicenter study examined the PK and probability of pharmacokinetic-pharmacodynamic (PK-PD) target attainment i.v. in critically ill patients, with suspected or documented infection Gram-negative bacteria.